Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 diabetes is unknown. METHODS: In this phase 3b, open-label, controlled trial, adult participants with obesity but without type 2 diabetes were randomly assigned in a 1:1 ratio to receive the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or the maximum tolerated dose of semaglutide (1.7 mg or 2.4 mg) subcutaneously once weekly for 72 weeks. The primary end point was the percent change in weight from baseline to week 72. Key secondary end points included weight reductions of at least 10%, 15%, 20%, and 25% and a change in waist circumference from baseline to week 72. RESULTS: A total of 751 participants underwent randomization. The least-squares mean percent change in weight at week 72 was -20.2% (95% confidence interval [CI], -21.4 to -19.1) with tirzepatide and -13.7% (95% CI, -14.9 to -12.6) with semaglutide (P<0.001). The least-squares mean change in waist circumference was -18.4 cm (95% CI, -19.6 to -17.2) with tirzepatide and -13.0 cm (95% CI, -14.3 to -11.7) with semaglutide (P<0.001). Participants in the tirzepatide group were more likely than those in the semaglutide group to have weight reductions of at least 10%, 15%, 20%, and 25%. The most common adverse events in both treatment groups were gastrointestinal, and most were mild to moderate in severity and occurred primarily during dose escalation. CONCLUSIONS: Among participants with obesity but without diabetes, treatment with tirzepatide was superior to treatment with semaglutide with respect to reduction in body weight and waist circumference at week 72. (Funded by Eli Lilly; SURMOUNT-5 ClinicalTrials.gov number, NCT05822830.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Tirzepatide also leads to greater weight loss than semaglutide for people with type 2 diabetes 14 and than liraglutide for people with obesity.15”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [15]
In the citing paper
“In the STEP-8 trial, 70 semaglutide 2•4 mg/week led to greater weight loss (a 15•8% reduction) compared with liraglutide 3•0 mg once daily (a 6•4% reduction); in the SURMOUNT-5 trial, 15 tirzepatide 15 mg caused significantly higher weight reduction (20•2%) compared with semaglutide 2•4 mg (13•7%”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [15]
In the citing paper
“in the SURMOUNT-5 trial, 15 tirzepatide 15 mg caused significantly higher weight reduction (20•2%) compared with semaglutide 2•4 mg (13•7% )”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [15]
In the citing paper
“Similar differences in effectiveness are found when looking at reductions in waist circumference, systolic blood pressure, and serum triglycerides, with differences in effect sizes reflecting the differences in weight loss in response to liraglutide, semaglutide, and tirzepatide treatment.15,70”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [15]
In the citing paper
“The efficacy of GLP-1 receptor agonists (GLP-1 RAs) in older adults has been robustly demonstrated in randomized controlled trials (RCTs) [34], providing strong evidence for their use in managing obesity and related comorbidities in individuals aged over 65.”
From A Narrative Review on GLP-1 Receptor Agonists for Obesity in Older Women: Maximizing Weight Loss While Preserving Lean Mass (2026) · cites this paper as [34]
15 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1998) · PsycEXTRA Dataset · doi:10.1037/e565682010-001 · Cited by 9,472
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437739.71477.ee · Cited by 2,735
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Whelton, P. K. (2002) · JAMA · doi:10.1001/jama.288.15.1882 · Cited by 1,473
Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
Malhotra, A., Grunstein, R. R., Fietze, I., Weaver, T. E., Redline, S., Azarbarzin, A., Sands, S. A., Schwab, R. J., Dunn, J. P., Chakladar, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404881 · Cited by 871
Self-citationTwo-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02026-4 · Cited by 868
Cited by
Items 501–590 of 590
GLP-1 medications: use and interest in a representative survey of Finns
Jallinoja, P. T., Pietiläinen, K. H., & Chang, V. W. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02149-5 · Cited by 2
Obesity and cardiovascular disease: Mechanistic insights and multimodal management strategies
Polu, P. R. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100729
Romaniuk, A., Salash, S., Koza, A., Karcz, A., Pająk, B., Bołdys-Żegocki, H., Majewski, J., Kaniecka, M., Dworniczak, M., & Wróblewska, O. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5070
Reappraising obesity management in the GLP-1 receptor agonist era
Christmas, T., Ahmed, A. R., & Tan, T. (2026) · npj Metabolic Health and Disease · doi:10.1038/s44324-026-00126-0
Future Directions in the Medical Treatment of Obesity: A Narrative Review
Bassatne, A., & Rizo, I. M. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03576-6 · Cited by 2
Ji, L., Yang, G., HUANG, Y., Ding, H., Xie, D., Jiang, X., Yuan, X., Cao, Z., Chan, 邹. Z., Zhang, H., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71193
Li, S., Yu, J., Wei, J., & Liang, M. (2026) · Medicine · doi:10.1097/md.0000000000050605
Kuo, C.-Y., Wu, J.-Y., Tsai, Y., Lai, C.-C., & Wang, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1880132
Beyond glycemic control: clinical cardiovascular effects of tirzepatide—a narrative review
Alawad, A. O., Merghani, T. H., Fadelelmoula, T. E. Y., Elamin, N. A., Satti, S., Edris, A., Hakim, A., El-Hindi, R. F., Alhaj-Ali, A. A., Ibrahim, W. E., et al. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188261469947 · Cited by 1
Tirzepatide for weight and behavior management in a patient with Smith-Magenis syndrome
Liao, X. C., Huang, T., Hong, D. S., & Luo, L. (2026) · JCEM Case Reports · doi:10.1210/jcemcr/luag152
Ayoub, M., Tsutsumi, T., & Rinella, M. E. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70921 · Cited by 2
Vutiglabridin overcomes the GLP-1 RA-associated weight-loss plateau to achieve normal body weight
Lee, H. M., Marakkalage, K. G., Kim, S. H., Lee, S., Lee, J. H., Park, H. S., & Yoo, S. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02161-9
Efficacy and safety of semaglutide for obesity and hyperphagia in adults with Prader-Willi syndrome
Shahd, A., Bridges, N., & Goldstone, A. P. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1881392 · Cited by 1
Wu, J., Lin, Y.-M., Hsu, W., Liu, T.-H., Tsai, Y., Huang, P., Chuang, M., & Lai, C. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1769425
Ouyang, Y., Zhong, W., Chen, L., Tang, W., Cao, X., Chu, X., Zhu, D., & Feng, W. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08838-4
Optimized Protocols to Extract Total Transcripts and Proteins from Lipid-Rich Tissues
de Azevedo, N., Lozano, A., Parsons, R. E., & Martin, T. C. (2026) · Methods and Protocols · doi:10.3390/mps9020065
Brancatisano, A., & Ryan, B. (2025) · Obesity Science & Practice · doi:10.1002/osp4.70097 · Cited by 2
Yetgin, M. K., Gletsu-Miller, N. A., Chapman, R. F., Gelber, E., Snyder, J., Gregg, D., & Nabhan, D. C. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100335
Mallette, J. H., Speed, J. S., Lirette, S. T., Moore, D., & Clemmer, J. S. (2026) · Obesity · doi:10.1002/oby.70180
Keskinler, M. V., Özgül, M., Koç, D., Kanlıçay, I., & Oğuz, A. (2026) · doi:10.2196/preprints.113096
Jastreboff, A. M., Ard, J. D., Hall, K. D., Kaplan, L. M., Krumholz, H. M., Name, M. A. V., Ryan, D. H., & Drucker, D. J. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag025 · Cited by 1
Mizdrak, M., Batistic, D., & Mizdrak, I. (2026) · Medical Sciences · doi:10.3390/medsci14050577
Hoog, M. M., Vallarino, C. R., Maldonado, J. M., Grabner, M., Teng, C., Terrell, K. A., & Richard, E. L. (2026) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2026.32.10.1173
Sattar, N. A., Mamas, M. A., Li, R., García‐Pérez, L., Chen, K. L., Upadhyay, N., Glass, L., Batterham, R. L., Dimitriadis, G. K., & Liu‐Seifert, H. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag408
Self-citationTroshina, E. A., Antsiferov, M. B., As, A., Bakulin, I. G., Galstyan, G. R., Маркова, Т. Н., Romantsova, T. I., Mazurina, N. V., & Koteshkova, O. M. K. (2026) · Problems of Endocrinology · doi:10.14341/probl13784 · Cited by 2
Sattar, N. A. (2025) · Obesity · doi:10.1002/oby.70017
The Role of Incretins in Obstructive Sleep Apnea “ GLP1RAs and GLP1RA / GIPRAs in OSA ”
Fuentes, A. L., Dhami, G., Pettus, J., Akuthota, P., & Malhotra, A. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70170 · Cited by 1
Lee, T., Lee, T.-I., Higa, S., Kao, Y., & Chen, Y. (2026) · Journal of Biomedical Science · doi:10.1186/s12929-026-01288-1
Mitochondrial remodeling as a effector of glp-1 therapy in obesity and diabetes: review
Alhindi, Y. Z. (2026) · Journal Of Advanced Pharmacy Education And Research · doi:10.51847/bfye5lnqza
Olaniyi, A. O., Gogineni, K. K., Olaniyi, H., Sabir, H., Eboigbe, G. A., Yerima, S. R., & Gabriels, N. (2026) · Cureus · doi:10.7759/cureus.114962 · Cited by 1
Murugadoss, K., Venkatakrishnan, A., & Soundararajan, V. (2026) · npj Metabolic Health and Disease · doi:10.1038/s44324-026-00131-3
Emerging Cardiorenal Protective Therapies in Lupus Nephritis
Capón, I. M., Sandino, J., Galindo, M., & Morales, E. (2026) · Drugs · doi:10.1007/s40265-026-02337-7 · Cited by 2
EFFECTIVENESS OF SEMAGLUTIDE IN OBESITY TREATMENT AND THE ROLE OF LIFESTYLE INTERVENTIONS
Bracichowicz, F., Winogrodzki, I., Kowalczyk, P., Paszkiewicz, H., Nowak, K., Gęsińska, A., Stryczek-Schlusche, A., Trzciński, B., Gugała, O., & Furczyńska, A. M. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3931
Eloralintid als neuer Amylinrezeptoragonist zum Gewichtsmanagement
Schürfeld, R. (2025) · Die Diabetologie · doi:10.1007/s11428-025-01404-z
Ma, T., & Luping, R. (2026) · Precision medication. · doi:10.1016/j.prmedi.2026.100115
Integrating lifespan biology into obesity science
Suliman, S. G. I., & Sargent, J. L. (2026) · Metabologia · doi:10.1007/s44357-026-00005-7
Evolving indications for metabolic and bariatric surgery
Wills, M. V., & Corcelles, R. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.06.009
Kunicki, M., Katulska, Z., Wolert, W., & Kunicka, A. (2026) · Maturitas · doi:10.1016/j.maturitas.2026.109025
Helsted, M. M., FONNESBECH-WULFF, C. C., Schaltz, N. L., Lund, I. W., Forman, J. L., Nielsen, C. K., Englund, A., Hartmann, B., Vilsbøll, T., Holst, J. J., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00075-6
Madsen, N., Coates, L. C., Merola, J. F., Ho, W., Hsueh, W. A., Kiltz, U., Ranganath, V. K., Deodhar, A. A., Troum, O. M., Diaz, C., et al. (2026) · RMD Open · doi:10.1136/rmdopen-2025-006577
Self-citationPaccola, G. P., de Oliveira, R. F., Mochetti, M. M., Razera, F. P. M., Vecchi, R., & Montanher, R. C. P. (2026) · Clinical Obesity · doi:10.1111/cob.70111 · Cited by 1
Senatorska, N., Kleszczewska, K., Pruska, A., Rarok, J., Godlewska, D., Pietruszewska, H., Banaszek, M., Panfil, A., Błocka, J., & Lurka, A. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4225
Effect of Tirzepatide on Cardiovascular Outcomes
Huston, J., Orey, D., Ashchi, A., Lachapelle, A. A., Genovese, A., Jackson, J., Ashchi, R., Ashchi, T., Ashchi, M., Sutton, D., et al. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00767-4 · Cited by 1
The Paradox and Future of GLP-1/GIP Combination Therapies: Efficacy and Mechanisms
Davies, I., Holst, J. J., ROSENKILDE, M. M., & Tan, T. (2026) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-061824-043740 · Cited by 3
Agboola, F. O., Fahim, S. M., Lin, G. A., Lee, W., Richardson, M., & Rind, D. M. (2026) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2026.32.5.631 · Cited by 3
Pedicino, D., & Liuzzo, G. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag550
Vera-Ponce, V. J. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100308
The effect of GLP-1RAs and co-agonists on body composition across obesity and type 2 diabetes
Sun, L. L., Liu, H. F., Zhang, X., Zuo, F., Kong, Y., Feng, J., & Nian, X. (2026) · European journal of medical research · doi:10.1186/s40001-026-04534-2
Mazzone, P. M., Giacoppo, D., Ammirabile, N., Mauro, M. S., Spagna, F., & Capodanno, D. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag430
Merolla, A., & Rovere, P. Q. (2026) · Cardiac failure review · doi:10.15420/cfr.2026.22
Obesity, incretin-based therapies, and cardiovascular disease in women
Salih, M., Sloots, Y. A. J., Hemels, M. E. W., Meems, L. M. G., Leening, M. J. G., & Ghossein‐Doha, C. (2026) · Netherlands Heart Journal · doi:10.1007/s12471-026-02084-0
Beyond the Skinfolds: Diagnostic and Therapeutic Hope for the Obese and Formerly Obese
Miller, D. D. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.07.014
Finding Common Ground: Updates from ObesityWeek 2025
Millard, A. J. (2026) · Journal of Cardiac Failure - Intersections · doi:10.1016/j.yjcafi.2026.04.005
Alam, A. (2026) · Bangladesh Journal of Endocrinology and Metabolism · doi:10.4103/bjem.bjem_17_26
Gupta, R., Sunner, S. S., & Lam, A. P. (2026) · Current Opinion in Physiology · doi:10.1016/j.cophys.2026.100930
Cardiometabolic drugs after stroke: time to embrace SGLT2 inhibitors and incretin-based therapies?
Ihle‐Hansen, H., Ihle-Hansen, H., Blauenfeldt, R. A., Dawson, J., Diederichsen, S. Z., & Hagberg, G. (2026) · Frontiers in Stroke · doi:10.3389/fstro.2026.1918465
Patil, M., Piccinini, F., Johnstone, E. K. M., Casari, I., & Falasca, M. (2026) · Bioscience Reports · doi:10.1042/bsr20250114 · Cited by 1
Daggolu, J., Okonkwo, M., & Chen, H. (2026) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002145
Theocharidou, E., Arvanitakis, K., Koufakis, T., Tsochatzis, E. A., Francque, S., & Germanidis, G. S. (2026) · Drugs · doi:10.1007/s40265-026-02362-6 · Cited by 1
Gender aspects of cardiovascular risks: current state of the problem and Ukrainian content
Gubska, O., Sharayeva, M. L., Tkachenko, V. I., Panin, A. V., & Kuzminets, A. A. (2026) · HYPERTENSION · doi:10.22141/2224-1485.19.1-2.2026.392
Trends in glucagon-like peptide-1 receptor agonist utilization and expenditure in Croatia
Belančić, A., Štiglić, M. K., Fajkić, A., Jelaković, A., Pećin, I., Reiner, Ž., Jelaković, B., & Vitezić, D. (2026) · Journal of International Medical Research · doi:10.1177/03000605261470651
Efficacy and safety of tirzepatide in the treatment of obesity and obesity-associated comorbidities
Sakhnova, E. E., Gavrilova, N. A., Ostroumova, O. D., Кочетков, А. И., Telkova, S. S., & Moryakova, Y. S. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-324
Maslin, K., Shawe, J., Blowers, S., Ceulemans, M., Hart, K. H., Schoenmakers, S., Rottenstreich, A., Hopper, H., Jensterle, M., Flynn, A. C., et al. (2026) · Obesity Reviews · doi:10.1111/obr.70203 · Cited by 3
Synchronizing obesity management with survodutide
Lonardo, A., & Weiskirchen, R. (2026) · Exploration of Drug Science · doi:10.37349/eds.2026.1008175
The Possible Link Between Tirzepatide and Pulmonary Embolism: A Case Report and a Narrative Review
Arecco, A., Cocchiara, F., & Maggi, D. C. (2026) · Endocrines · doi:10.3390/endocrines7020020
Davis, S. C., Patel, S. V., Fletcher, S., McLaughlin, J. P., Deren, M. E., & Piuzzi, N. S. (2026) · European Journal of Orthopaedic Surgery & Traumatology · doi:10.21203/rs.3.rs-10744245/v1 · Cited by 1
Current trends in pharmacotherapy of overweight and obesity
Ürgeová, A., & Kozárová, M. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.099
Bruenderman, E. H., Eisa, M., Pearlman, M. Y., & Mundi, M. S. (2026) · Current Surgery Reports · doi:10.1007/s40137-026-00537-4
Stéatohépatite associée à un dysfonctionnement métabolique (MASH) : prise en charge
Farrugia, M. A., Gual, P., & Anty, R. (2026) · EMC - Hépatologie · doi:10.1016/s1155-1976(25)50657-5
Metabolic advances in 2025: from clinical breakthroughs to molecular reprogramming
Dalamaga, Μ., & Liu, J. (2026) · Metabolism Open · doi:10.1016/j.metop.2026.100442 · Cited by 2
Adipositas: neue medikamentöse Therapien
Seufert, J. (2026) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2610-3294
Clinical Potential of GIP in Type 2 Diabetes and Obesity
Nauck, M. A., Gribble, F. M., Reimann, F., D’Alessio, D. A., & Campbell, J. E. (2026) · Diabetes Care · doi:10.2337/dci25-0141 · Cited by 3
GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology
Fano, M. D., Haurum, L. L., Andreasen, C. R., Porcellati, F., & Andersen, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70888 · Cited by 5
Incretins for obesity: closer to a nicotine patch than a silver bullet
Dippel, I., Adelman, M., Olson, K. M., Holt, A., Collins, J., Reddest, A., & Carris, N. W. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2557458
Malbert, C., Delarue, J., & Guéant, J. (2026) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2026.07.004 · Cited by 1
Alali, M., Naveed, A. K., Alnounou, A., Alharami, M., & Nashed, B. (2026) · Cureus · doi:10.7759/cureus.109979 · Cited by 1
Duun, O. M., Dichman, M.-L., Lindschou, J., Scragg, J., Petersen, J. J., Bojsen-Møller, K. N., Jebb, S. A., Gluud, C., & Dirksen, C. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-111336
Pharmacological progress in obesity: tirzepatide’s rising advantage over semaglutide
Khan, S., Afridi, H., Mahato, R. K., Zubair, M., Khan, U., & Ullah, S. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000004507 · Cited by 1
Rasool, Z. K., Shah, R., Batool, A. E. Z., Shah, R., Khachatryan, M., Bhardwaj, S., Ali, A., Atta, M., Bakthavatchalam, P., Khawar, M. M. H., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1903335 · Cited by 1
Lee, H., Min, Y. W., Oh, Y. E., Kim, T., Min, B., Lee, J. H., & Rhee, P. (2026) · Biomedicines · doi:10.3390/biomedicines14091887
Weekly Journal Scan: REDEFINing the next generation of obesity pharmacotherapy
Liuzzo, G., & Patrono, C. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf628
Bauer, E. (2026) · CME · doi:10.1007/s11298-026-4619-y
Khan, M. M., Imam, H., Mondal, N. T., et al. (2025) · TAJ Journal of Teachers Association · doi:10.70818/taj.v38i04.0887
Lipid sensing and brain hormone receptors in food intake and glucose regulation
Garrido, A. N., Lyons, S. A., MOSLEMIAN, D., Beaudry, J. L., & Lam, T. K. T. (2026) · Nature Reviews Endocrinology · doi:10.1038/s41574-026-01278-1
Domagała, K., Abramowicz, A. D., Rumin, M., Tatarata, O., Osuch, M., Osuch, M., Kiełboń, A., Jaciubek, M., Luty, C., & Reklewska, Z. O. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.5125
Metadata
- Authors
- Aronne, L. J., Horn, D. B., le Roux, C. W., Ho, W., Falcon, B. L., Gomez Valderas, E., Das, S., Lee, C. J., Glass, L. C., Senyucel, C., & Dunn, J. P.
- Affiliations
- Weill Cornell Medicine (US)
- University of Texas Center for Obesity Medicine and Metabolic Performance, Department of Surgery, University of Texas McGovern Medical School, Houston
- Diabetes Complications Research Centre, Conway Institute, University College Dublin, Dublin
- University of California, Los Angeles (US)
- Eli Lilly, Indianapolis
- Eli Lilly (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-07-03
- Volume
- 393
- Issue
- 1
- Pages
- 26-36
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4410277932
- Cited by
- 634
- References
- 40
- Citations by year
- 2026: 448 · 2025: 186
- FWCI
- 355.83
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- eCommons (Cornell University) (submittedVersion, cc-by-nc-nd)
- Funders
- Eli Lilly and Company (NA)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- tirzepatide, semaglutide, obesity, weight loss, waist circumference, GLP-1 receptor agonists, GIP/GLP-1 receptor agonist, gastrointestinal adverse effects, non-diabetic obesity
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Semaglutide, Adult, Aged, Body Weight, Female, Humans, Injections, Subcutaneous, Male, Middle Aged, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents, Maximum Tolerated Dose, Glucagon-Like Peptide 1, Waist Circumference
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.